Arkadiusz Zbigniew Dudek MD PhD, FACP

Gastrointestinal Cancer, Genitourinary Oncology, Melanoma, Thoracic Cancer

Professor of Medicine in the Division of Hematology, Oncology, and Transplantation, University of Minnesota Professor of Medicine in the Division of Hematology/Oncology University of Illinois Hospital & Health Sciences System

Join to view full profile

200 1st St SWRochester, MN 55905
Phone+1 507-284-2511

Dr. Dudek is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dudek's full profile Already have an account?

Summary

I am board certified in hematology and oncology. I specialize in treatment of lung cancer, mesothelioma, melanoma, pancreatic cancer, and kidney cancer. I lead Early Phase Therapeutic Program for The Cancer Care Center, Regions Hospital, HealthPartners. I am a member of Phase 1 Program at The University of Minnesota.

Education & Training

Military Medical InstitutePh.D., 1998
University of MinnesotaFellowship, Hematology and Medical Oncology, 1994 - 1997
UPMC Medical Education (Harrisburg)Residency, Internal Medicine, 1991 - 1994
Medical University of WarsawClass of 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

WI State Medical License 2026 - 2027
MN State Medical License 1994 - 2026
IL State Medical License 2012 - 2020
PA State Medical License 1991 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
COMPLETED
PHASE1
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
COMPLETED
PHASE1
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
WITHDRAWN
PHASE2

Publications & Presentations

PubMed

Clinical Outcomes of Minibeam Radiotherapy for Superficial Skin and Soft Tissue Malignancies.
Kiran K Chauhan, Michael P Grams, Minji K Lee, Sean S Park, Anne W Rajkumar
International Journal of Radiation Oncology, Biology, Physics. 2026-08-14
Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2.
Mohamed A Aboelatta, Jabra Zarka, Nika Tchatchua, Noureldin A Aboelatta, Jeffrey E Johnson
Current Oncology. 2026-06-24
Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study.
Mohamed A Aboelatta, Ali Rezazadeh, Ugur Sener, William G Breen, Riham Suleiman
Melanoma Research. 2026-06-01

Journal Articles

Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era
Abern MR1, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ, Anticancer Res, 5/1/2014
Radiation recall reaction causing cardiotoxicity
Masri SC, Misselt AJ, Dudek A, Konety SH, J Cardiovasc Magn Reson, 4/22/2014
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Ganesan C1, Obulareddy SJ, Fischer JH, Antonysamy MA, Jha G, Bliss RL, Dudek AZ, Am J Clin Oncol, 2/26/2014

Books/Book Chapters

Devita, Hellman and Rosenberg's Cancer Review
Chapter: Treatment of Metastatic Cancer.
Dudek AZ, Govindan, RLippincott Williams & Wilkins, Hagerstwon2009
Tumor Angiogenesis Frontiers in Anti-Cancer Drug Discovery
Chapter: Review of Selected Patents for Cancer Therapy Targeting.
Page 741 - 757M.N. Kirstein, A.Z. Dudek

Abstracts/Posters

"Melanoma and Glioblastoma Multiforme 2011 ASCO Abstracts"
Arkadiusz Dudek, MD, PhD, Best of ASCO Ecuador-2011, Salinas, Ecuador, 7/29/2011
Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carci...
Figlin R. A., Nicolette C. A., Amin A., Dudek A., Logan T., Lance R. S., Holzbeierlein J. M., Pal S. K., Master V. A., DeBenedette M., Tcherepanova I.Y., Jain R., Wil..., J Clin Oncol, 1/1/2011
Clinical evaluation of food effects on pharmacokinetics of the novel oral taxane, tesetaxel.
Danesi H., Dudek A., Spindler E., Alcorn Jr H, J Clin Oncol, 1/1/2011

Lectures

Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression afte...
2019 ASCO Annual Meeting - 6/1/2019
Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Grand Rounds: "Tailoring Oncology Care with Genomics"
Department of Medicine, University of Illinois - 5/28/2013

Press Mentions

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352February 27th, 2023
First Test of Anti-Cancer Agent PAC-1 in Human Clinical Trials Shows PromiseDecember 22nd, 2022
Post-ASCO News Alert: Merck’s KEYNOTE-564 Data Heralds Early Adjuvant Keytruda Use in Renal CancerJune 17th, 2021